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Importance of blood pressure control in hemodialysis patient patients, however, the relationship between blood pres-
survival. sure (BP) and mortality is controversial. Several studies
Background. In the general population, hypertension is the have reported that hypertension is a risk factor for mor-leading cause of cardiovascular mortality. In dialysis patients,
tality [8–11]. Other studies have suggested that hyperten-however, the relationship between blood pressure (BP) and
sion may not have a major adverse effect on mortalitymortality is controversial. We analyzed this relationship in he-
modialysis (HD) patients. of hemodialysis (HD) patients [12–16]. It has been also
Methods. The study population included 405 patients who observed that low BP is associated with increased mortal-
had survived at least two years on HD. The observation period ity [12, 14, 15], and some results suggest a U-curve rela-was initiated at the beginning of the third year. Predialysis BP
tionship between BP and CV mortality [14].measurements of all the dialysis treatments performed during
The present study analyzes the relationship betweenthe second year of HD was collected as the baseline data.
Mean systolic BP (SBP) and mean diastolic BP (DBP) were BP and mortality in HD patients, using the Cox propor-
calculated. Demographic and comorbidity data were collected tional hazard regression model [17] and adjusting for
at the start of the observation period (beginning of third year
demographic and comorbidity variables.of HD). Mortality was analyzed at the end of the follow-up
(death or December 31, 1998; total mortality), during the first
two years of follow-up (years 3 and 4 of HD; early mortality)
METHODSand after the second year of follow-up ($5 years of HD; late
mortality). All of the 405 patients who survived at least two years
Results. In the multivariate analysis, SBP and DBP were of HD therapy, and were treated in five centers in Monte-
significantly associated with death. The adjusted total mortalit-
video between January 1, 1981 and December 31, 1998ies were U shaped. When early mortality was analyzed, only
were retrospectively included. The data were collectedlow BP (DBP ,74.5 mm Hg) was significantly associated with
mortality. When late mortality was analyzed, only high BP prospectively in a central database. The mean age (mini-
(SBP .160 mm Hg) was significantly associated with mortality. mum–maximum) of the patients was 62.1 6 16.6 (16 to
In the early deaths, a cardiac cause was significantly less fre- 88) years old; 163 (40.2%) were women, and 2.2% werequent, while withdrawal and malignancy were more frequent
black. There were 12.3% diabetic patients. Data regard-than in late deaths.
ing the comorbidities and treatment regimens are givenConclusions. This study confirms that hypertension is a risk
factor for mortality in HD patients, and shows the importance in Table 1. The observation period began at the third
of the length of the follow-up time to demonstrate this relation- year on dialysis. The median (range) follow-up time was
ship. The low frequency of a cardiac cause in the early death 2.74 (0.1 to 12.2) years, and the follow-up of 18 patientsgroup suggests that the association between hypotension and
was more than 10 years. The total risk exposition timemortality in HD patients is not related to cardiovascular causes,
was 1390 patient-years. At the end of the follow-up pe-and only reflects the association between hypotension and
other severe medical conditions. riod, 134 patients were dead, 21 were transplanted, 6
were changed to continuous ambulatory peritoneal dial-
ysis, and 36 were transferred to other centers. In no case
In the general population, hypertension is the leading was the transfer because of medical complications. If
cause of cardiovascular (CV) mortality [1–7]. In dialysis any patient died in the three months after the transfer,
he or she was considered dead in this analysis.
Predialysis BP, demographic, and comorbidity dataKey words: systolic blood pressure, diastolic blood pressure, hypoten-
sion, dialysis mortality, low blood pressure. were considered independent variables for the analysis.
Predialysis BP was the average of systolic BP (SBP) andReceived for publication September 17, 1999
diastolic BP (DBP) measured in all the dialysis treat-and in revised form March 21, 2000
Accepted for publication May 15, 2000 ments performed during the second year on dialysis. A
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Table 1. Patient characteristics at the start of the observation period received 12 hours of dialysis per week in three sessions.
(beginning of the third year of hemodalysis) (N 5 405)
Cuprophane hollow fiber dialyzers were used in the early
Mean6SD or percent years, and cellulose acetate, cellulose diacetate, or poly-
Demographics sulfone hollow fiber dialyzers were used in later years.
Age years 62.1616.6 Reuse was the norm. The diet and other medical pre-
Minimum age 16
scriptions were as previously described [9].Maximum age 88
Sex % female 40.2
Race % black 2.2 Statistical analysis
Comorbidities
The survival analysis was done with the Kaplan-MeierCerebrovascular disease % yes 9.6
Diabetes % yes 12.3 method. Univariate and multivariate analyses of survival
Chronic pulmonary disease % yes 13.8 were performed to identify significant risk factors. The
Smokers % yes 33.3
multivariate analysis was done using the Cox propor-Heart disease % yes 28.1
Malignancy % yes 4.9 tional hazard regression model [17]. BMDP statistical
Peripheral vascular disease % yes 8.1 software was used. Survival time was measured from the
Alcoholism % yes 18.8
start of the observation period until death from any causeVascular access
Graft % yes 19.8 or the last date of follow-up alive. Patients receiving a
Complications % yes 18.0 transplant were censored at the date of the transplant.
Kt/V 1.1060.23
The transferred patients were censored three monthsSerum albumin g/dL 3.9760.49
Hematocrit % 29.164.5 after the transfer.
Blood pressure Mortality was analyzed as follows: (1) total mortality,
Predialysisa
defined at the end of the follow-up as death, transplant,Systolic mm Hg 142617
Diastolic mm Hg 8168 or living as of December 31, 1998; (2) early mortality,
Systolic .140 % yes 59.3 death during the first two years of follow-up (which was
Systolic .150 % yes 30.6
actually years 3 and 4 of the patient on HD); and (3)Diastolic .90 % yes 8.7
Antihypertensive medicationa % yes 45.2 late mortality, defined as death after the second year
of follow-up ($5 years of HD). SBP and DBP werea During the second year on dialysis
considered to be categorical variables. The JNC-VI cate-
gories of BP were used to define the high BP groups
[19], and the low quintile of nonhypertensive patients
healthcare professionals measured BP with the patient in was considered to be in the low BP group. The numbers
a sitting position. Phases I and V of Korotkoff sounds of patients in the different SBP categories were as fol-
were used to determine SBP and DBP, respectively. lows: nonhypertensive group (,140 mm Hg) 165 pa-
The following demographic and comorbidity data and tients; hypertensive stage I group (140 to 159 mm Hg)
treatment characteristics were collected at the start of 186 patients; hypertensive stage II group (160 to 179
the observation period: sex, age, race, type of vascular ac- mm Hg) 50 patients; and hypertensive stage III group
cess, use of antihypertensive drugs, dialysis dose (Kt/V), ($180 mm Hg) 4 patients. The hypertensive groups in
hematocrit, serum albumin, and presence or absence of stages II and III were merged, and thus four groups were
previous history of diabetes, chronic obstructive pulmo- considered: low BP (,119.4 mm Hg), reference group
nary disease, arteriosclerotic heart disease, cerebrovascu- (119.4 to 139 mm Hg), high BP stage I (140 to 159
lar disease, cardiac failure, peripheral vascular disease, mm Hg), and high BP stages II and III ($160 mm Hg).
malignancy, vascular access complications, smoking habit, The number of patients in the different DBP categories
and alcoholism. The definition of these variables was was as follows: nonhypertensive group (,90 mm Hg)
previously described [9, 18]. Comorbid conditions devel- 369 patients, hypertensive stage I group (90 to 99 mm Hg)
oping after the start of the observation period were not 30 patients, hypertensive stage II group (100 to 109) 5
taken into account. patients, and patients in the hypertensive stage III group
The same nephrologists took care of these patients 0 ($110 mm Hg). Hypertensive group stages I and II
during their follow-up time. The aims of the treatment were merged, and three groups were considered: low BP
included: maintaining the patients free of symptoms and (,74.5 mm Hg), reference group (74.5 to 89 mm Hg), and
rehabilitated; predialysis BP was lower than 140/90, and high BP ($90 mm Hg). The analysis of the relationship
predialysis blood urea nitrogen was below 80 mg/dL; between BP and mortality was adjusted for all of the
normalized total dialysis dose was higher than a Kt/V demographic and comorbidity data and treatment char-
urea of 1.0 before 1990 and 1.2 after this year; the normal- acteristic variables introduced in the model.
ized total catabolic rate was higher than 1.2 g/kg/day; The frequencies of causes of mortality in early and
potassium was ,5.8 mEq/L, calcemia was between 9 and late deaths were compared. Suicide was included into the
“withdrawal” cause. Mesenteric thrombosis and aortic11 mg/dL, and phosphorus was ,6 mg/dL. Most patients
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Table 2. Cox proportional hazard regression model method: cations, smoking habit, heart disease, cerebrovascular
Forward stepwise (likelihood ratio)
disease, peripheral vascular disease, sex, alcoholism, di-
Variable P Relative risk (95% CI) alysis dose (Kt/V), hematocrit, and albumin plasmatic
Age ,0.0001 1.0322 1.0189 1.0456 level, showed that SBP and DBP were significantly asso-
Diabetes 0.0047 1.8544 1.2082 2.8461 ciated with mortality. The adjusted mortality and risk
Chronic pulmonary disease 0.0100 1.7559 1.1439 2.6953
for SBP and DBP were U shaped. Total mortality wasMalignancy 0.0195 2.0208 1.1197 3.6473
Arteriovenous graft 0.0121 1.7335 1.1280 2.6639 significantly higher when DBP was $90, or DBP was
Cerebrovascular disease 0.1558 ,74.5 mm Hg (Fig. 1).
Heart disease 0.2536
When early mortality (3 and 4 years of HD) was ana-Hematocrit 0.2554
Smokers 0.2792 lyzed, only low BP was significantly associated with mor-
Sex 0.5227 tality. DBP lower than 74.5 mm Hg had a relative risk
Serum albumin 0.5425
(RR) of 2.52 (P 5 0.0042), and those with a SBP lowerKt/V 0.7323
Antihypertensive medication 0.8287 than 119.4 mm Hg had a RR of 2.42 (P 5 0.2025; Fig. 2).
Alcoholism 0.8672 SBP lower than 110 mm Hg compared with SBP equal
Peripheral vascular disease 0.9370
or higher than 110 mm Hg had a RR (95% CI) of 3.91
Based on 405 patients who underwent 134 events. (range 1.32 to 11.55, P 5 0.0135).
When late mortality (death at $5 years of HD) was
analyzed, only a high BP was significantly associated with
mortality. Patients with a SBP equal to or higher thananeurysm leak were included into the “peripheral vascu-
160 had a RR of 2.19 (P 5 0.0472), and DBP equal orlar disease” cause.
higher than 90 had a RR of 1.75 (P 5 0.1546; Fig. 3).
Those with DBP values equal to or higher than 95 com-
RESULTS pared with DBP lower than 95 had a RR (95% CI) of
Survival from the initiation of the observation period 4.12 (1.62 to 10.45, P 5 0.0029).
(start of year 3 of HD) was 90.6, 75.8, and 61.3% at one, The most frequent causes of death were CV diseases
three, and five years, respectively (thus corresponding (36.5%) and infection (21.6%). A comparison between
to years 3, 5, and 7 of the patient on HD therapy). The the early and late deaths shows that a cardiac cause was
Cox proportional hazard regression model identified five significantly less frequent in early deaths than in those
variables that were significantly and independently asso- who died later (12.3 vs. 31.9%, P 5 0.0066). Among
ciated with survival: age, diabetes, cancer, chronic pul- patients who died early, the causes of withdrawal of treat-
monary disease, and vascular access complications (Ta- ment (18.8 vs. 2.5%, P 5 0.0807) and malignancy (7.7
ble 2). vs. 2.9%, P 5 0.2126) were more prevalent (Table 3).
Blood pressure values (mean 6 SD) during the second The comparison between the 65 patients who died
year of dialysis were SBP 142 6 17 mm Hg and DBP early and the other 340 patients showed that the first
81 6 8 mm Hg. There were 240 patients with an average group was older (P 5 0.001) and with more patients
SBP equal to or higher than 140 mm Hg (59.3%), and diagnosed with diabetes (P 5 0.001), chronic pulmonary
124 patients with a SBP equal to or higher than 150 disease (P 5 0.0017), malignancies (P 5 0.0003), AV
mm Hg (30.6%). Only 35 patients (8.7%) had an average graft (P 5 0.0083), or vascular access complications (P 5
DBP equal to or higher than 90 mm Hg. The number 0.0269). On the other hand, there was no difference in
of patients treated with antihypertensive medication CV complications between both populations (Table 4).
was 183 (45.2%); 151 (37.3%) received one drug, and
32 (7.9%) received two or three drugs. The most fre-
DISCUSSIONquently used antihypertensive agents were calcium chan-
Our study, in agreement with previous reports [8–11],nel blockers (22.9% mostly nifedipin), angiotensin-con-
confirms that hypertension is a risk factor for mortalityverting enzyme inhibitors (21.4%), b blockers (8.1%),
in HD patients. We also observed that the risk of deathand sympathetic blockers (7.5%). The number of pa-
linked to BP is U shaped. Low BP is associated withtients treated with antihypertensive medication in differ-
increased mortality, in agreement with the reports ofent groups of DBP was as follows: 29 (83.3%) patients
several authors [12, 14–16].with an average DBP $ 90 mm Hg and 146 (50.5%)
The relationship between BP and mortality in dialysispatients with average DBP values between 75 and 89
patients remains controversial. There has been consider-mm Hg. Only 7 out of 80 patients (8.8%) with an average
able discussion regarding whether hypertension is a riskDBP lower than 75 mm Hg received antihypertensive
factor for mortality, whether hypotension is associatedmedication.
with increased CV mortality, and how much BP mustThe multivariate analysis, including age, diabetes, can-
cer, chronic pulmonary disease, vascular access compli- be lowered to minimize mortality. We believe that our
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Fig. 1. Adjusted relative risk of death for differ-
ent levels of blood pressure (BP) control (Cox
proportional hazard regression model). Symbols
and abbreviations are: ( ) SBP, systolic blood
pressure; (h) DBP, diastolic blood pressure. P
values are versus the reference value.
Fig. 2. Adjusted relative risk of early deaths
for different levels of BP control (Cox propor-
tional hazard regression model). Symbols and
abbreviations are ( ) SBP, systolic blood
pressure; (h) DBP, diastolic blood pressure.
P values are versus the reference value.
Fig. 3. Adjusted relative risk of late deaths for
different levels of BP control (Cox proportional
hazard regression model). Symbols and abbrevi-
ations are: ( ) SBP, systolic blood pressure;
(h) DBP, diastolic blood pressure (DBP). P
values are versus the reference.
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Table 3. Causes of death and a mean of 248 BP measurements per patient. Charra
et al attributed the excellent survival observed in theirEarly deaths Late deaths
N565 N569 P center to improved BP control [10]. They reported a
Cardiac 12.3% 31.9% 0.0066a survival of 75 and 43% at 10 and 20 years of HD, respec-
Cerebrovascular 13.8% 8.7% 0.3446 tively, in 445 unselected HD patients with a MAP of 99
Peripheral vascular 7.7% 5.8% 0.6614
mm Hg. Even in this population, mostly normotensiveInfection 16.9% 26.1% 0.1980
Malignancy 7.7% 2.9% 0.2126 according to the usual approach, there were significantly
Withdrawal 7.7% 1.4% 0.0807 less CV and all-cause mortalities in the subgroup with
Other 15.4% 13.0% 0.6978
MAP less than 99 mm Hg. Mortality was 24.0 and 48.6Unknown 18.5% 10.1% 0.1678
death per 1000 patient-years in the low BP groupa Significant
(MAP 5 89.5 6 8.3 mm Hg) and in the high BP group
(MAP 5 109.0 6 8.3 mm Hg), respectively.
On the other hand, several reports of large HD popula-
Table 4. Comorbidities in patients who survived or died during the
tions were unable to demonstrate a significant relation-first two years of the observation period
ship between elevated BP and increased mortality in HD
Patients dead Patients living patients [12–16, 24]. It has been suggested that hyperten-N565 N5340 Chi2 sion may not have a major adverse effect on the mortality
P%
of HD patients [12, 13]. In 1996, Salem and Bower re-
Diabetes 24.6 10.0 0.0010a ported that hypertensive patients have half of the RRChronic pulmonary
of dying when compared with normotensive patients indisease 26.2 11.5 0.0017a
Malignancy 13.8 3.2 0.0003a a prospective cohort followed for one year [12]. In 1998,
Arteriovenous graft 33.3 17.2 0.0083a Zager et al found neither systolic nor diastolic predialysisArteriovenous access
hypertension were associated with an increase in CVcomplications 27.7 16.2 0.0269a
Smokers 36.9 32.6 0.5028 mortality [14]. In 1999, Port et al explored the relation-
Heart disease 32.3 27.4 0.4157 ship between BP and mortality in a national randomPeripheral vascular
sample of 4499 U.S. HD patients [15]. No associationdisease 13.8 8.8 0.2085
Age (mean6SD) 68.4614.8 60.8616.7 ,0.001ab with an elevated mortality risk could be observed for
a Significant predialysis hypertension, except for an elevated risk of
b Student’s t-test cerebrovascular deaths.
Several possible explanations exist for the discrepanc-
ies between these reports and the results in the general
population. The effect of hypertension as a risk factorstudy contributes to a better understanding of this impor-
tant problem. for mortality, while well established in the general popu-
lation, requires long-term longitudinal studies in ESRDAvailable data in the general population show that
hypertension is a major risk factor for stroke and coro- patients. Discrepancies observed in the different studies
may be related to the duration of the follow-up and thenary heart disease and that it is the leading cause of
CV mortality [1–7]. On the other hand, coronary heart overall mortality rate of the population analyzed. Our
study shows the importance of a longer follow-up period.disease, stroke, and sudden death remain the main causes
of death among patients receiving chronic HD therapy We found that hypertension was a significant risk factor
for late mortality. However, if only the first two yearsin all published registries [20–23].
Although the relationship between BP and CV mor- of follow-up had been considered, we would not have
been able to demonstrate any relationship between hy-bidity and mortality is very strong in the general popula-
tion, only a few studies reach a similar conclusion in pertension and mortality. The follow-up time of several
studies that were unable to demonstrate an associationESRD patients. Degoulet et al reported that persistent
hypertension in HD patients significantly decreased sur- between hypertension and mortality was short, between
12 and 46 months [12, 14, 15].vival [8]. They analyzed 1451 patients taking the average
of predialysis BP measurements in the follow-up (mean The lack of an association between BP and mortality
observed in some studies may reflect the overall poor160 measurements per patient). Survival at 36 months
was 84.1, 78.7, and 65% in patients with mean SBP below prognosis of the population analyzed. The association
may be overshadowed by the high mortality in the pa-140 mm Hg, between 140 and 159, and above 160, respec-
tively. We found that a mean arterial pressure (MAP) tient population in the same studies. The mortality rate
of the population we analyzed was 9.64 per 100 patient-higher than 115 mm Hg increases the risk of failure in
a simultaneous analysis of morbidity and mortality [9]. years, which was lower than that of the population in
other studies [12, 14, 15]. Five and 10 year survival ratesWe studied 104 patients during a follow-up period of
two years. The analysis included 22 potential risk factors of all of the patients treated in our centers from January 1,
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1981 to December 31, 1998 were 62.7 and 39.8%, respec- Port et al [15] have reported a U-shaped relationship
between postdialysis BP and mortality, and it is necessarytively [25].
The difference between the usual (that is, the average to clarify the actual meaning of this observation.
Another important problem is the controversy regard-BP of an individual over several years) and the baseline
BP values was analyzed by MacMahon et al in the gen- ing whether or not hypotension is associated with an
increment of CV mortality. In the general population,eral population [7]. He estimated that the relationship
between the usual DBP value and vascular disease is at a J curve relationship between treated DBP and CV
mortality has been described [29–32], suggesting that lowleast 60% stronger than between baseline DBP and vascu-
lar disease (regression dilution bias). This problem has not BP may be associated with an increased CV mortality.
On the other hand, Stamler, Stamler, and Neaton havebeen studied in HD patients, but considering that individ-
ual BP fluctuations are accentuated in these patients (ow- pointed out that the relative risk of ischemic heart dis-
ease, stroke, CV mortality, and all-cause mortality in theing to variable fluid overloading), the regression dilution
bias may be even more important than in the general U.S. population increases stepwise at each level above
the optimal SBP of 120 and DBP of 80 mm Hg [6].population. Some studies that were unable to demonstrate
hypertension as a risk factor in HD patients were often In the dialysis population, a significant correlation be-
tween low predialysis SBP and mortality has been re-based on a single baseline BP measurement at the start
of the study [16]. In others, BP measurements were taken ported by several studies based on large cohorts of pa-
tients [14, 15, 33]. Iseki et al studied a total of 1243for 1 week [15], 1 month [12], or 90 days [14] at the
beginning of the study. The BP value in our study was patients undergoing HD with lengthy follow-up (5110.3
patient-years) and a low annual mortality rate (6.69 deathsthe average of one year of measurements before the start
of the study (a mean of 152 measurements per patient). per 100 patient-years) [16]. The death rate shows an
inverse correlation with DBP, determined prior to theIt has been suggested that the antihypertensive medi-
cation may explain the survival advantages of hyperten- first dialysis session. The adjusted odds ratio (95% CI)
of death was 0.84 (0.71 to 0.99) for each 10 mm Hg whensive patients observed in some studies. Salem and Bower
reported that hypertensive patients have half of the RR the reference was less than 69 mm Hg. Zager et al found
that predialysis SBP ,110 mm Hg was associated withof dying when compared with normotensive patients,
whereas untreated hypertensive patients had a mortality an increased CV mortality [14]. The association was ob-
served in both models, when SBP was analyzed as fixedrate that was no different from that of the normotensive
patients [12]. Zager et al also confirmed this observation covariate at baseline (RR 5 1.64, range 1.22 to 2.20)
and as a time-dependent covariate (RR 5 3.07, 2.50 toregarding the survival benefit of antihypertensives [14].
Our analysis showed no association between antihyper- 3.76). Port et al found a significant association between
low predialysis SBP and adjusted mortality risk (RR 5tensive medication and mortality.
Other differences of the analyzed population may ex- 1.86 for SBP ,110 mm Hg, P , 0.0001) [15]. The ele-
vated mortality risk associated with low predialysis SBPplain the observed discrepancies. The comparison of our
population with others, especially with the U.S. dialysis indicated similar patterns for both the diabetic and non-
diabetic subgroups and for patients with and withoutpopulation, shows several disparities. The proportion of
black people and the prevalence of diabetes were mark- congestive heart failure or coronary artery disease.
A possible pathophysiological explanation of the ele-edly lower in our population (Table 1) than in the U.S.
dialysis patients [12, 14, 20]. BP control in our population vated risk associated with low SBP is that low SBP could
be an effect from heart failure or for severe autonomic(Table 1) was better than that reported in Zager et al’s
patients (53.5% with a SBP over 150 mm Hg, and 16% neuropathy. The hypothesis that heart disease is a con-
tributor to this high mortality risk is supported by thewith a DBP over 90 mm Hg) and that in the U.S. HD
population (53% with SBP over 150 mm Hg and 17% study of Foley et al [24]. They reported that each 10
mm Hg increase in MAP was associated with an in-with a DBP over 90 mm Hg) [14]. The frequency of
congestive heart failure was lower in our population creased RR for development of left ventricular hypertro-
phy (RR 1.48, P 5 0.020), de novo cardiac failure (RR(15.8%) than in Port et al’s study (41.9%) [15], while
age and gender were similar. 1.44, P 5 0.007), and de novo ischemic heart disease
(RR 1.39, P 5 0.051). Paradoxically, MAP was inverselyThis discussion is focused on predialysis BP measure-
ments because BP monitoring has suggested that predial- associated with early mortality (RR 0.82, P 5 0.009).
Cardiac failure preceded 65% of all deaths in this study,ysis BP values reflect the interdialytic BP more accu-
rately [26, 27]. Use of postdialysis BP measurements is and it confounded the true impact of hypertension. MAP
among patients who developed cardiac failure fell fromof doubtful value because it is a transient reading that
is dependent on the removed fluid and the vascular re- 103 6 10 to 98 6 13 mm Hg (P , 0.0001). Among
patients who developed cardiac failure, low MAP wassponse. BP usually increases in the next few hours to
the predialysis level [28]. However, Zager et al [14] and the strongest predictor of mortality (RR 1.43 per 10
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mm Hg fall, P , 0.0001). Data suggest that hypertension the association between hypotension and severe medical
conditions. Hypotension in some patients might be aleads to cardiomyopathy and subsequent cardiac failure,
a highly lethal condition. Following the development marker of severe disease [33]. The causal disease of these
severe medical conditions, for example, malignancy inof cardiac failure, hypotension predicts mortality and is
likely to be a marker for the severity of cardiac disease our patient population, could be the cause of death, and
hypotension only another clinical manifestation of the[24]. Data suggest that the inverse relationship between
BP, averaged from the start of ESRD until death, and causal disease. The multivariate model we used to con-
trol for confounding variables certainly does not fit themortality reflects the fact that cardiac failure has oc-
curred prior to death [24]. Similar conclusions have been complex associations of determinants with mortality per-
fectly, and a more detailed clinical investigation is neces-reached by Port et al in the subanalysis according to heart
disease groups [15]. The mortality rate was particularly sary to provide better control for the confounding char-
acteristics.elevated among those HD patients with low BP who also
had congestive heart failure or coronary artery disease. Our study confirms that hypertension is a risk factor
for mortality in HD patients and shows the importanceHowever, a similar trend also appeared among those
without any recorded heart disease. They conclude that of accumulating data over a longer follow-up time to
demonstrate this relationship. The low frequency of car-the presence of coexisting heart disease provides only a
partial explanation for the observed excess risk in the diac cause in the early deaths suggests that the associa-
tion between hypotension and mortality in HD patientslow-BP group [15]. In our study, cardiac diseases were
not the leading cause of death in early mortality, and is not related to cardiovascular causes and only reflects
the association between hypotension and other severecongestive heart failure had a low frequency at the start
and during the observation period. medical conditions.
Another possible explanation is that malnourished
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